Cerdulatinib
- Generic Name
- Cerdulatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N7O3S
- CAS Number
- 1198300-79-6
- Unique Ingredient Identifier
- D1LXQ45S1O
- Background
Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04757259
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Portola Pharmaceuticals
- Registration Number
- NCT04021082
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT01994382
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath